OBN (UK) Ltd

?? BioTrinity Programme Announcement ?? During the Business & Investment track at BioTrinity, we’ll be delivering a CEO Spotlight session featuring 4 innovative and boundary-pushing life sciences CEOs who will discuss questions about the challenges they and others in their network face. ? The panellists will share their insights into: ?? What the CEO role entails ??Their experiences of building a strong team, working with investors and board members ??The importance of communication and storytelling Expert Panellists: ?? Chair: Adam Workman: Head of Investments & New Ventures at Oxford University Innovation Jenny Button: Founder and CEO at Emm Jonathan Kwok: Founder and CEO at Infinitopes James Field: Founder and CEO at LabGenius Therapeutics Dr. Carina Kern: Founder and CEO at LinkGevity Have you booked your ticket for BioTrinity in London yet? Don’t miss this chance to attend OBN's flagship 2-day conference on 1st & 2nd April 2025. ?? Register for your ticket today: www.biotrinity.com #LifeSciences #BiotechInnovation

We'd like to share the BioTrinity Bronze package, crafted to amplify your brand’s visibility in the biotech, pharma, and investment communities. Here’s what’s included: ?? 4 delegate passes included to attend our flagship 2-day conference. You’re not just boosting visibility, you’re building relationships and fostering connections that last beyond the event. ??Unparalleled Branding: Feature your brand in all pre-event and on-event marketing, including a half-page advert in the handbook, capturing the attention of industry leaders. ??Exclusive Exposure: 1.2m wide exhibition stand - you supply the artwork and OBN creates and assembles your stand (it's then yours to take away at the end!) The bronze package comes with a price of ￡9000 + VAT (Discounts available for OBN members). ?? Learn more at www.biotrinity.com or contact Emma Durham for details. Our current sponsors include: ?EBD Group ?WuxiAppTec ?The Oxford Science Park (TOSP) ?ERBC ?SGS CDMO Solutions (Quay Pharma) #BioTech #Pharma #LifeSciences #Networking #BrandVisibility #Networking

Thank you to everyone who attended the OBN BioTuesday last night, spotlighting the latest R&D in Metabolic Disease and Obesity, and to our host for the night, FTI Consulting. ? The evening featured updates from all corners of the industry, including Big Pharma, Patient Advocacy as well as R&D SMEs working on a range of treatments and solutions; with?thanks to: ? Matthew Coghlan,?Vice President - Head Incretin Portfolio Science at Eli Lilly and Company? Giorgio Castagneto Gissey,?CEO of Keyron Medical Technology? Adrien Lemoine,?Co-Founder and Chief Executive Officer, Bloomsbury Genetic Therapies? Jon Rees,?CEO at MitoRx Therapeutics? Sarah Le Brocq,?UK Head of Public Affairs, Reset Health, founder of All About Obesity CIC? Ryan Lafferty,?CEO of Dia Beta Labs Ltd? ? Here at OBN we organise monthly BioTuesday, so if you are keen to attend next time, view our upcoming events here: https://lnkd.in/ehwNTUfN.

?? BioTrinity Programme Announcement ?? During the Business & Investment track at BioTrinity, we’ll be delivering a session that delves into the world of 'Building an inclusive and collaborative culture to thrive in times of change'. We’ve assembled a panel packed with experts, so another hugely valuable session for life sciences execs to attend at BioTrinity: ?? Chair: Dr Ewa Truchanowicz FRSA, CEO at Bidshaper Daniel Harrison: AIML Specialist at Amazon Web Services (AWS) Rebecca Godfrey PhD: COO at ExpressionEdits Zsolt S.: Head of People Advisory Services at BDO Andrew M. Davies: Director - Leasing at ARC | Advanced Research Clusters Group Have you booked your ticket for BioTrinity in London yet? Don’t miss this chance to attend OBN's flagship 2-day conference on 1st & 2nd April 2025. ?? Register for your ticket today: www.biotrinity.com #LifeSciences #BiotechInnovation

?? BioTrinity Programme Announcement ?? Our science spotlight sessions at BioTrinity showcase innovative R&D companies at around Series A stage across 14 therapy areas. Here we are showcasing the companies joining 'The Immunology & Inflammation' showcase: ?? Showcasing companies: Jenny Bailey Cooper: CEO & Co-Founder at Ferryx Ashwin Menon Nandakumar: CEO & Co-Founder at Granza Bio (YC W24) Gil Beyen: CEO at Montis Biosciences Josselin Caradec: Curlew Bio Lucas Decuypere: CEO & President at Allegro Biotech David Sarphie: CEO at Seroxo Limited Don’t miss this chance to attend OBN's flagship 2-day conference on 1st & 2nd April 2025. ?? Book your ticket today: www.biotrinity.com #LifeSciences #BiotechInnovation #OBN

We would like to extend a warm welcome to some new OBN Members - ISOgenix Limited, Facilipharma, Zenzero, Global Impact Ventures Inc (GIVE), PhotoClear and Ignota Labs. We look forward to working with you!

?? BioTrinity Programme Announcement ?? ?? Our Science Spotlight sessions at BioTrinity showcase industry-leading & innovative R&D companies at around Series A stage across 14 different therapy areas. Here we are pleased to share details of the companies joining the Cell & Gene Therapy Spotlight session, kindly hosted by ARC | Advanced Research Clusters. ?? Session Host: Andrew M. Davies, Director - Leasing at Advanced Research Clusters Showcasing companies: Simon Bornschein, Founder & CEO at Coding Bio Marina Tarunina, Director at Plasticell Limited Rafael E. Carazo Salas, Founder & CEO at CellVoyant David Venables, CEO at Laverock Therapeutics Giles Dudley, CBO at Stimuliver David Hipkiss, Executive Chair at AlveoGene Have you booked your ticket for BioTrinity in London yet? Don’t miss this chance to attend OBN's flagship 2-day conference on 1 & 2 April 2025. ?? Book your ticket today: www.biotrinity.com #LifeSciences #BiotechInnovation #OBN

?? BioTrinity Programme Announcement ?? Our Science Spotlight sessions at BioTrinity showcase industry-leading & innovative R&D companies at around Series A stage across 14 different therapy areas. Here we are pleased to share details of the companies joining one of the Oncology Science Spotlight sessions: ?? Session host: Helen Tayton-Martin: Chief Business & Strategy Officer at Adaptimmune Showcasing companies: Dr. Ramsay McFarlane: CEO at Awen Oncology Irina Babina: CEO at Concr Robert D. Ladner, Ph.D.: CEO at CV6 Therapeutics, (NI) Ltd. Dr. Steve Emery: CSO at CHAIN Biotechnology Ltd David Beadle: CEO at APOBEC Discovery Kevin Maskell: CEO & CSO at Bioarchitech Ltd Have you booked your ticket for BioTrinity in London yet? Don’t miss this chance to attend OBN's flagship 2-day conference on 1 & 2 April 2025. ?? Book your ticket today: www.biotrinity.com #LifeSciences #BiotechInnovation #OBN

?? Have a spare hour this week? Check out OBN's latest Power Hour video by Pierre-Micha?l Coly from Leads To Development on Non-Clinical Aspects of Drug Development?? The presentation covers the nonclinical drug development process, including pharmacology, pharmacokinetics, and toxicology, and touches on clinical dose selection. It outlines regulatory requirements for clinical trial applications and emphasises the importance of an integrated development plan to navigate regulatory challenges efficiently. Watch here: ??https://ow.ly/B87m50V2R79 L2D brings deep expertise in supporting biotech companies across CMC, nonclinical (toxicology, efficacy, and pharmacokinetics), and clinical development. Interested in attending other OBN events? Check out our upcoming events: https://lnkd.in/ehwNTUfN

Are you a life sciences company and looking to get recognised? On Thursday 10th April, 2025, Science & Engineering Health Technologies Alliance (SEHTA) will be holding the SEHTA 2025 Healthcare Business Awards at the London Institute for Healthcare Engineering. ??The deadline for applications is the 28th February!?? For more information, please see below. Good luck!